Enzo Biochem Inc
ENZ.N- Latest Trade
- trading lower2.7USD
- Change
- -0.03
- % Change
1.10%Negative
- As of Aug 16 2022. Values delayed up to 15 minutes
- Day Range
- 2.70 - 2.74
- 52-Week Range
- 1.99 - 4.14
- Previous Close
- 2.73
- Open
- 2.73
- Volume
- 5,569.00
- 3 Month Average Trading Volume
- 1.48
- Shares Out (Mil)
- 48.72
- Market Cap
- 133.01
- Forward P/E
- -99,999.99
- Dividend Yield
- -99,999.99
Key Statistics
mean rating - analysts
- P/E Excl. Extra Items (TTM)
- -99,999.99
- Price To Sales (TTM)
- 1.19
- Price To Book (Quarterly)
- 2.14
- Price To Cash Flow (Per Share TTM)
- -99,999.99
- Total Debt/Total Equity (Quarterly)
- 7.19
- Long Term Debt/Equity (Quarterly)
- 6.81
- Return On Investment (TTM)
- -8.02
- Return On Equity (TTM)
- -6.03
2021 (millions USD)
About Enzo Biochem Inc (ENZ.N)
Company Information
Enzo Biochem, Inc. (Enzo) is an integrated diagnostics, clinical lab, and life sciences company that is focused on delivering and applying advanced technology to produce reliable products and services for clinical needs. The Company develops, manufactures and sells technology solutions and platforms to clinical laboratories, specialty clinics, researchers and physicians globally. Enzo's segments include Enzo Clinical Lab, Enzo Life Sciences and Enzo Therapeutics. Enzo Clinical Lab is a clinical reference laboratory providing a range of clinical services to physicians, medical centers, other clinical labs and pharmaceutical companies. Enzo Life Sciences manufactures, develops and markets products and tools for clinical research, drug development and bioscience research customers worldwide. Enzo Therapeutics is a biopharmaceutical venture that developed multiple novel approaches in the areas of gastrointestinal, infectious, ophthalmic and metabolic diseases.
Address
60 EXECUTIVE BLVDFARMINGDALE, NY
11735
United States
Industry
Healthcare Facilities
Executive Leadership
- Hamid Erfanian
- Chief Executive Officer, Director
- David A. Bench
- Chief Financial Officer, Senior Vice President, Treasurer, Corporate Secretary
- Kara Cannon
- Chief Operating Officer
- Matthew Kupferberg
- General Counsel
- Dieter Schapfel
- Chief Medical Director, Enzo Clinical Labs
- Mary Tagliaferri
- Lead Independent Director
- Elazar Rabbani
- Director
- Bradley L. Radoff
- Independent Director
- Ian B. Walters
- Independent Director
Markets Performance
Official Data PartnerCommodities
| Future | Last | % Change |
|---|---|---|
| Gold | 1,773.20 | -- |
| Copper | 666.70 | -- |
| Brent Crude Oil | 92.73 | 0.42%Positive |
| CBOT Soybeans | 1,467.50 | 0.91%Positive |
Stocks
| Index | Last | % Change |
|---|---|---|
| S&P 500 | 4,305.20 | 0.19%Positive |
| Euro STOXX 50 | 3,805.22 | -- |
| FTSE 100 | 7,536.06 | 0.36%Positive |
| Nikkei 225 | 29,101.33 | 0.81%Positive |
Source: Refinitiv, an LSEG business - data delayed by at least 15 minutes